Soteria is developing next-generation small-molecule-activated ‘protein switches’ for controlling the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.

LocationSan Francisco, CA
Partner Ken Haas